A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma

Trial Profile

A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Duvelisib (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRAVURA
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 28 Jun 2016 According to an Infinity Pharmaceuticals media release, the company has taken a strategic decision to close this trial.
    • 28 Jun 2016 According to an Infinity Pharmaceuticals media release, status changed from recruiting to discontinued.
    • 23 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top